, Volume 233, Issue 13, pp 2503–2511 | Cite as

Quinolone antibiotics and suicidal behavior: analysis of the World Health Organization’s adverse drug reactions database and discussion of potential mechanisms

  • Julie Samyde
  • Pierre Petit
  • Dominique Hillaire-Buys
  • Jean-Luc FaillieEmail author
Original Investigation



Several case-reports suggest that the use of quinolones may increase the risk of psychiatric adverse reactions such as suicidal behaviors.


The aim of this study is to investigate whether there is a safety signal for quinolone-related suicidal behaviors in a global adverse drug reactions database.


All antibiotic-related adverse reactions were extracted from VigiBase, the World Health Organization (WHO) global Individual Case Safety Report (ICSR) database. Disproportionality analyses were performed to investigate the association between reports of suicidal behavior and exposure to quinolones, in comparison with other antibiotics.


From December 1970 through January 2015, we identified 992,097 antibiotic-related adverse reactions. Among them, 608 were quinolone-related suicidal behaviors including 97 cases of completed suicides. There was increased reporting of suicidal behavior (adjusted reporting odds ratios [ROR] 2.78, 95 % CI 2.51–3.08) with quinolones as compared to other antibiotics. Candidate mechanisms for quinolone-induced suicidal behaviors include GABAA antagonism, activation of NMDA receptors, decreased serotonin levels, oxidative stress, and altered microRNA expressions.


We found a strong safety signal suggesting an increased risk of suicidal behaviors associated with quinolone use. Plausible psychopharmacological mechanisms could underlie this association. Further investigations are urgent to confirm and better understand these findings.


Psychopharmacology Adverse drug reactions Suicidal behaviors Suicide Quinolones 



The Uppsala Monitoring Centre has provided the data, but the study results and conclusions are those of the authors and not necessarily those of the Uppsala Monitoring Centre, National Centres, or WHO.


All authors participated in the study design. JLF acquired the data. JS did the statistical analyses and wrote the initial draft. All authors critically revised the manuscript.

Compliance with Ethical Standards

Conflict of interest

This study was not funded. The authors declare that they have no conflicts of interest.

Research ethics

Since this study did not include individual patients and only studied the data of an existing and anonymously recorded database, ethical approval was not needed.

Supplementary material

213_2016_4300_MOESM1_ESM.doc (36 kb)
ESM 1 (DOC 36 kb)
213_2016_4300_MOESM2_ESM.doc (70 kb)
ESM 2 (DOC 70 kb)
213_2016_4300_MOESM3_ESM.doc (75 kb)
ESM 3 (DOC 75 kb)
213_2016_4300_MOESM4_ESM.doc (37 kb)
ESM 4 (DOC 37 kb)
213_2016_4300_MOESM5_ESM.doc (40 kb)
ESM 5 (DOC 40 kb)
213_2016_4300_MOESM6_ESM.doc (40 kb)
ESM 6 (DOC 40 kb)
213_2016_4300_MOESM7_ESM.doc (38 kb)
ESM 7 (DOC 38 kb)
213_2016_4300_MOESM8_ESM.doc (40 kb)
ESM 8 (DOC 39 kb)


  1. Ahmed AI, van der Heijden FMMA, van den Berkmortel H, Kramers K (2011) A man who wanted to commit suicide by hanging himself: an adverse effect of ciprofloxacin. Gen Hosp Psychiatry 33(82):e5–7PubMedGoogle Scholar
  2. Akahane K, Sekiguchi M, Une T, Osada Y (1989) Structure-epileptogenicity relationship of quinolones with special reference to their interaction with gamma-aminobutyric acid receptor sites. Antimicrob Agents Chemother 33:1704–8CrossRefPubMedPubMedCentralGoogle Scholar
  3. Barthélémi L, Lebrun J (2015) Completed suicide and fluoroquinolones: a possible association. 19th Annual Meeting of French Society of Pharmacology and Therapeutics., 21–23 April 2015 Caen., France. Fundam Clin Pharmacol 29(suppl 1):65Google Scholar
  4. Bégaud B, Martin K, Haramburu F, Moore N (2002) Rates of spontaneous reporting of adverse drug reactions in France. JAMA 288:1588CrossRefPubMedGoogle Scholar
  5. Behera C, Krishna K, Singh HR (2014) Antitubercular drug-induced violent suicide of a hospitalised patient. BMJ Case Rep. 2014 published online Jan 6. doi:  10.1136/bcr-2013-201469
  6. Blondeau JM (2004) Fluoroquinolones: mechanism of action., classification., and development of resistance. Surv Ophthalmol 49(suppl 2):s73–8CrossRefPubMedGoogle Scholar
  7. Brown EG, Wood L, Wood S (1999) The medical dictionary for regulatory activities (MedDRA). Drug Saf 20:109–17CrossRefPubMedGoogle Scholar
  8. Dodd PR, Davies LP, Watson WE, Nielsen B, Dyer JA, Wong LS, Johnston GA (1989) Neurochemical studies on quinolone antibiotics: effects on glutamate, GABA and adenosine systems in mammalian CNS. Pharmacol Toxicol 64:404–11CrossRefPubMedGoogle Scholar
  9. Dukes MNG (2006) Fluoroquinolones. In: Meyler’s side effects of drugs: the international encyclopedia of adverse drug reactions and interactions, 15th edn. Elsevier Science, Amsterdam, pp 1396–407Google Scholar
  10. European Medicines Agency (EMEA) (2008) EMEA restricts use of oral norfloxacin drugs in UTIs. EMEA.
  11. European Medicines Agency (EMEA) (2008) EMEA recommends restricting the use of oral moxifloxacin-containing medicines. EMEA.
  12. Feinberg SS (1995) Fluoroquonolones-induced depression. Am J Psychiatry 152:954–5PubMedGoogle Scholar
  13. Fish DN (2001) Fluoroquinolone adverse effects and drug interactions. Pharmacotherapy 21:253S–272SCrossRefPubMedGoogle Scholar
  14. Ilgin S, Can OD, Atli O, Ucel UI, Sener E, Guven I (2015) Ciprofloxacin-induced neurotoxicity: evaluation of possible underlying mechanisms. Toxicol Mech Methods 25:374–81CrossRefPubMedGoogle Scholar
  15. Labay-Kamara U, Manning S, McMahon T (2012) Fluoroquinolone-induced suicidal ideation and suicidality. Psychosomatics 53:97–8CrossRefPubMedGoogle Scholar
  16. LaSalvia EA, Domek GJ, Gitlin DF (2010) Fluoroquinolone-induced suicidal ideation. Gen Hosp Psychiatry 32:108–10CrossRefPubMedGoogle Scholar
  17. Lewis RJ, Mohr JF 3rd (2008) Dysglycaemias and fluoroquinolones. Drug Saf 31:283–92CrossRefPubMedGoogle Scholar
  18. Li YJ, Xu M, Gao ZH, Wang YQ, Yue Z, Zhang YX et al (2013) Alterations of serum levels of BDNF-related miRNAs in patients with depression. PLoS One 8, e63648CrossRefPubMedPubMedCentralGoogle Scholar
  19. Lindquist M (2008) VigiBase, the WHO global ICSR database system: basic facts. Drug Inf J 42:409–19Google Scholar
  20. Lindquist M, Edwards IR (2001) The WHO programme for international drug monitoring, its database., and the technical support of the Uppsala monitoring center. J Rheumatol 28:1180–7PubMedGoogle Scholar
  21. Maes M, Galecki P, Chang YS, Berk M (2011) A review on the oxidative and nitrosative stress., O&NS pathways in major depression and their possible contribution to the., neurodegenerative processes in that illness. Prog Neuropsychopharmacol Biol Psychiatry 35:676–92CrossRefPubMedGoogle Scholar
  22. Martin RM, Kapoor KV, Wilton LV, Mann RD (1998) Underreporting of suspected adverse drug reactions to newly marketed, “black triangle” drugs in general practice: observational study. BMJ 317:119–20CrossRefPubMedPubMedCentralGoogle Scholar
  23. Mehlhorn AJ, Brown DA (2007) Safety concerns with fluoroquinolones. Ann Pharmacother 41:1859–66CrossRefPubMedGoogle Scholar
  24. Montané E, Barriocanal A, Isern I, Parajon T, Costa J (2009) Multiple drug interactions - induced serotonin syndrome: a case report. J Clin Pharm Ther 34:485–7CrossRefPubMedGoogle Scholar
  25. Moore N, Thiessard F, Begaud B (2005) The history of disproportionality measures, reporting odds ratio, proportional reporting rates in spontaneous reporting of adverse drug reactions. Pharmacoepidemiol Drug Saf 14:285–6CrossRefPubMedGoogle Scholar
  26. Mulhall JP, Bergman LS (1995) Ciprofloxacin induced acute psychosis. Urology 46:102–3CrossRefPubMedGoogle Scholar
  27. Oquendo MA, Mann JJ (2000) The biology of impulsivity and suicidality. Psychiatr Clin N Am 23:11–25CrossRefGoogle Scholar
  28. Oquendo MA, Sullivan GM, Sudol K, Baca-Garcia E, Stanley BH, Sublette ME, Mann JJ (2014) Toward a biosignature for suicide. Am J Psychiatry 171:1259–77CrossRefPubMedPubMedCentralGoogle Scholar
  29. Owens RC, Ambrose PG (2005) Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 41(suppl 2):s144–57CrossRefPubMedGoogle Scholar
  30. Pariente A, Grégoire F, Fourrier-Reglat A, Haramburu F, Moore N (2007) Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf 30:891–8CrossRefPubMedGoogle Scholar
  31. Pariente A, Didailler M, Avillach P, Miremont-Salamé G, Fourrier-Reglat A, Haramburu F, Moore N (2010) A potential competition bias in the detection of safety signals from spontaneous reporting databases. Pharmacoepidemiol Drug Saf 19:1166–71CrossRefPubMedGoogle Scholar
  32. Reinstatler L, Youssef NA (2015) Ketamine as a potential treatment for suicidal ideation: a systematic review of the literature. Drugs R D 15:37–43CrossRefPubMedPubMedCentralGoogle Scholar
  33. Rubinstein E (2001) History of quinolones and their side effects. Chemotherapy 47(suppl 3):3–8CrossRefPubMedGoogle Scholar
  34. Salvo F, Leborgne F, Thiessard F, Moore N, Bégaud B, Pariente A (2013) A potential event-competition bias in safety signal detection: results from a spontaneous reporting research database in France. Drug Saf 36:565–72CrossRefPubMedGoogle Scholar
  35. Schmuck G, Schürmann A, Schlüter G (1998) Determination of the excitatory potencies of fluoroquinolones in the central nervous system by an in vitro model. Antimicrob Agents Chemother 42:1831–6PubMedPubMedCentralGoogle Scholar
  36. Smalheiser NR, Lugli G, Rizavi HS, Torvik VI, Turecki G, Dwivedi Y (2012) Micro RNA expression is down-regulated and reorganized in prefrontal cortex of depressed suicide subjects. PLoS One 7, e33201CrossRefPubMedPubMedCentralGoogle Scholar
  37. Smalheiser NR, Zhang H, Dwivedi Y (2014) Enoxacin elevates microRNA levels in rat frontal cortex and prevents learned helplessness. Front Psychiatry 5:6CrossRefPubMedPubMedCentralGoogle Scholar
  38. Smith DA, Schmid EF (2006) Drugs withdrawals and the lessons within. Curr Opin Drug Discov Devel 9:38–46PubMedGoogle Scholar
  39. Sprandel KA, Rodvold KA (2003) Safety and tolerability of fluoroquinolones. Clin Cornerstone 5(suppl 3):s29–36CrossRefGoogle Scholar
  40. Stone M, Laughren T, Jones ML, Levenson M, Holland PC, Hughes A, Hammad TA, Temple R, Rochester G (2009) Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ 339:b2880CrossRefPubMedPubMedCentralGoogle Scholar
  41. Tomé AM, Filipe A (2011) Quinolones: review of psychiatric and neurological adverse reactions. Drug Saf 34:465–88CrossRefPubMedGoogle Scholar
  42. Tsuji A, Sato H, Kume Y, Tamai I, Okezaki E, Nagata O, Kato H (1988) Inhibitory effects of quinolone antibacterial agents on gamma-aminobutyric acid binding to receptor sites in rat brain membranes. Antimicrob Agents Chemother 32:190–4CrossRefPubMedPubMedCentralGoogle Scholar
  43. Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U (1990) Possible interaction of fluoroquinolones with the benzodiazepine-GABAA-receptor complex. Br J Clin Pharmacol 30:63–70CrossRefPubMedPubMedCentralGoogle Scholar
  44. Uppsala Monitoring Centre (2008). Uppsala Report 40: New import processs for ICSR. Uppsala Monitoring Centre.
  45. van der Heijden PG, van Puijenbroek EP, van Buuren S, van der Hofstede JW (2002) On the assessment of adverse drug reactions from spontaneous reporting systems: the influence of underreporting on odds ratios. Stat Med 21:2027–44CrossRefPubMedGoogle Scholar
  46. van Puijenbroek EP, Bate A, Leufkens HGM, Lindquist M, Orre R, Egberts ACG (2005) A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 11:3–10CrossRefGoogle Scholar
  47. Vargas HO, Nunes SO, Pizzo de Castro M, Bortolasci CC, Sabbatini Barbosa D, Kaminami Morimoto H et al (2013) Oxidative stress and lowered total antioxidant status are associated with a history of suicide attempts. J Affect Disord 150:923–30CrossRefPubMedGoogle Scholar
  48. Werner NL, Hecker MT, Sethi AK, Donskey CJ (2011) Unnecessary use of fluoroquinolone antibiotics in hospitalized patients. BMC Infect Dis 11:187CrossRefPubMedPubMedCentralGoogle Scholar
  49. WHO Collaborating Centre for Drug Statistics Methodology (2013) Guidelines for ATC classification and DDD assignment 2013.
  50. Zhanel GG, Noreddin AM (2001) Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections. Curr Opin Pharmacol 1:459–63CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Julie Samyde
    • 1
  • Pierre Petit
    • 2
  • Dominique Hillaire-Buys
    • 1
    • 3
  • Jean-Luc Faillie
    • 1
    • 4
    Email author
  1. 1.Department of Medical Pharmacology and ToxicologyCHU Montpellier University HospitalMontpellierFrance
  2. 2.Department of PsychiatryCHU Montpellier University HospitalMontpellierFrance
  3. 3.INSERM U1058, Faculty of MedicineUniversity of MontpellierMontpellierFrance
  4. 4.Laboratory of Biostatistics, Epidemiology and Public Health (EA 2415), Faculty of MedicineUniversity of MontpellierMontpellierFrance

Personalised recommendations